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Summary  
Inflammasomes are intracellular multiprotein signaling platforms that initiate 
inflammatory responses in response to pathogens and cellular damage. Active 
inflammasomes induce the enzymatic activity of caspase-1 resulting in the induction of 
inflammatory cell death, pyroptosis, and the maturation and secretion of inflammatory 
cytokines IL-1β and IL-18. Inflammasomes are activated in many inflammatory diseases, 
including autoinflammatory disorders and arthritis, and inflammasome-specific therapies 
are under development for the treatment of inflammatory conditions. In this review, we 
outline the different inflammasome platforms and recent findings contributing to our 
knowledge about inflammasome biology in health and disease. In particular we discuss the 
role of the inflammasome in the pathogenesis of arthritic diseases including rheumatoid 
arthritis, gout, ankylosing spondylitis and juvenile idiopathic arthritis, and the potential of 
newly developed therapies that specifically target the inflammasome or its products for the 
treatment of inflammatory diseases. 
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INTRODUCTION 
Inflammasomes are molecular complexes formed within the cytosol of innate immune cells 
1. Upon activation, these signaling platforms acquire a proteolytic activity that initiates 
inflammatory events such as the maturation of the pro-inflammatory cytokine interleukin 
1β (IL-1β) 2. Inflammasomes can detect various insults including the presence of pathogens 
and tissue damage 3. While the main physiological function of inflammasomes is to elicit 
an immune response and to contribute to the maintenance of tissue homeostasis and repair, 
deregulated inflammasome activation can be harmful. Several inflammasomes are directly 
linked to hereditary and acquired autoinflammatory diseases 4. The clinical importance of 
inflammasomes has also been demonstrated in diseases with a more complex etiology 
characterized by inflammation and tissue damage. Excess inflammasome activation has 
been shown to contribute to cancer, metabolic disorders including type 1 and type 2 
diabetes, neurodegenerative diseases and autoimmunity such as in systemic lupus 
erythematosus (SLE). Increased inflammasome response has also been suggested to be a 
hallmark of the aging process 5.  
Several pathologies of the joint are linked to aberrant inflammasome engagement. This was 
investigated in patients with gout, rheumatoid arthritis (RA), and juvenile idiopathic 
arthritis (JIA) 6.  
Understanding the mechanisms leading to the activation of inflammasomes in 
physiological and pathological conditions, will ameliorate the diagnosis and treatment of 
aberrant inflammation including in diseases with arthritis. Extensive efforts have been 
deployed in the last two decades to characterize how the different inflammasomes are 
activated or regulated. Several key discoveries have dramatically improved our 
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understanding of these pathways and led to the development of new therapeutic strategies 
aimed at targeting downstream mediators. Drugs that could directly target inflammasome 
assembly are being developed and could provide valuable tools to dampen inflammation 
in diseases with aberrant inflammasome activation. In this review we discuss major 
advances that improved our understanding of inflammasomes biology. We will also 
highlight several key questions that are still open. In particular, we will focus on how the 
different inflammasomes contribute to different arthritic disease.  
 
NLRs function as sensors of pathogen and cellular perturbations 
Classical inflammasome pathways are engaged by the oligomerization of pattern-
recognition receptors (PRR) following direct or indirect recognition of pathogen effectors 
or perturbations in cellular homeostasis (Figure 1). Among these receptors, the nucleotide-
binding leucine-rich repeat receptors (NLRs) were among the first characterized. These 
proteins are typical PRR that can assemble signaling platforms with specific enzymatic 
activities, often referred under the generic name of signalosomes 7. Several NLRs such as 
NLRP3 can form molecular structures harboring the enzymatic properties of typical 
inflammasomes. The generic modular organization of NLR proteins is formed by a 
conserved tripartite domain structure consisting of a N-terminal recruiting domain, a 
central nucleotide-binding domain that is capable of oligomerization, and a C-terminal 
leucine rich repeat (LRR) domain that regulates the assembly of the complex. This modular 
organization is found in several innate immune pathways in mammals as well as in plants 
where they form the largest family of defense molecules 8,9. While plant and mammalian 
NLRs are structurally and functionally very similar, they are believed to be the product of 
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convergent evolutions 10, indicating that this successful modular architecture may 
underline a possible conserved strategy of cellular host defenses. 
The central conserved region of plant and mammalian NLRs consists of a NTPase domain. 
This domain is found in a widespread family of signal transduction ATPases with 
numerous functions that includes the apoptosome protein Apaf-1 11.  The NTPase domain 
is believed to function as a very rapid molecular switch`, that cycles between an adenosine 
5′-diphosphate (ADP)–bound inactive state and an adenosine 5′-triphosphate (ATP)–bound 
active state 12. Upon engagement, Apaf-1 oligomerizes to assemble an apoptosome 
complex. Similarly, NLRs assemble specific signalosomes such as inflammasomes. Both 
active inflammasomes and the apoptosome recruit caspases that will provide proteolytic 
effector functions. The apoptosome recruits directly the proapoptotic caspase-9. Similarly, 
the NLRC4 protein recruits directly the inflammatory caspase, caspase-1, while other 
NLRs such as NLRP3 recruit caspase-1 indirectly via the adaptor protein ASC 13 (Figure 
1A).  
The NLRP3 inflammasome can be activated by a wide variety of stimuli, apparently 
unrelated. It can detect pathogens, including bacteria and viruses, as well signals released 
by exposure to damaging particles or drugs thereby eliciting a sterile inflammation. Most 
NLRP3 activators trigger a form of cellular stress that correlates with changes in ion 
content of the cell. A typical hallmark of NLRP3 activation is the efflux of potassium ions 
(K+) 14, a phenomenon that is also required for the assembly of the apoptosome 15.  Another 
feature of NLRP3 activation is the disruption of the trans-Golgi network (TGN) 16. NLRP3 
activation was also observed upon disruption of other organelles such as lysosomal rupture, 
and mitochondrial malfunction (reviewed in 17). In response to various stimuli, NLRP3 
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translocates to disrupted TGN leading to inflammasome formation 16. This, suggests that 
TGN disruption could be the central sensing mechanism of NLRP3 activation possibly 
downstream of signals emerging from damaged mitochondria or lysosomes.  
The pro-inflammatory role of NLRP3 was initially demonstrated by the discovery of its 
role in promoting cryopyrin-associated periodic syndrome (CAPS) 18. CAPS is an inherited 
autoinflammatory disorder characterized by systemic inflammation with fever often 
presenting with skin rashes and central nervous system inflammation. While arthralgia is 
common in patients with CAPS, arthritis is less frequent 19. Inflammation in CAPS is 
caused by gain-of-function mutations in NLRP3 leading to aberrant inflammasome 
activation and direct initiation of an inflammatory cascade20. These findings demonstrated 
that inflammasome activation per se was sufficient to initiate a full-blown systemic 
inflammation in humans. 
The NLRP1 inflammasome differs from other NLRs by the addition of a C-terminal 
extension made of a FIIND domain and a CARD. Caspase-1 is mainly recruited to NLRP1 
through interactions with the C-terminal CARD (Figure 1A). In the process of activation, 
the FIIND undergoes self-cleavage, an event that is required for activation. NLRP1 
responds to the enzymatic activities of pathogen effectors such as the Lethal Toxin (leTox) 
from Bacillus anthracis 21as well as by non-pathogen-associated triggers such as the drug 
Val-boro Pro, an anti-cancer molecule that inhibits the cytosolic serine proteases Dpp8 and 
Dpp9 22,23.  
Gain of function mutations within NLRP1 have bene described in humans to cause 
uncontrolled inflammasome activation promoting a familial autoinflammatory skin disease 
associated with cancer 24. Other mutations within NLRP1 have been linked to 
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autoinflammation with arthritis and dyskeratosis (AIADK) also known as NAIAD 
(NLRP1-associated autoinflammation with arthritis and dyskeratosis)25. Moreover, 
polymorphisms in NLRP1 were found to be associated with immune disorders such as 
vitiligo and rheumatoid arthritis 26, further highlighting the importance of this pathway in 
humans as a host defense pathway whose alteration can predispose to autoimmune or 
autoinflammatory diseases 27.  
CARD8 is a caspase recruitment domain-containing protein, also known as TUCAN or 
Cardinal, which is structurally very similar to NLRP1 Although its N-terminus is much 
shorter than that of NLRP1, CARD8 also contains a FIIND domain and a CARD at its C-
terminus. CARD8 was initially discovered as a 48kDa protein expressed in various tissues 
and cell types 28. To date, up to five mRNA isoforms have been described that encode for 
CARD8 proteins with divergent N-terminal but equal C-terminal regions 29. CARD8 does 
not respond to pathogen effectors including Lethal Toxin therefore CARD8 was considered 
to be a decoy NLR which may inhibit inflammasome activation. Interestingly, CARD8 
inhibits NLRP3 inflammasome activity but not NLRP1. In fact, similar to NLRP1, CARD8 
activates caspase-1 and induces pyroptosis when cells were treated with Val-boro Pro 30.  
CARD8 knock-down resulted in enhanced IL-1β secretion when using NLRP3 activating 
stimuli. Furthermore, CARD8 was unable to bind to CAPS-associated mutant NLRP3 
possibly contributing to the overactive NLRP3 inflammasome in these patients 31. CARD8 
has evolved to play a role in the delicate balance of activating and inhibiting signals that 
determine NLRP3 inflammasome activity. Disturbance of such balance may contribute to 
the development of inflammatory diseases which is probably why CARD8 polymorphisms 
are often associated with risk for arthritic diseases 32-36. 
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Other NLR inflammasomes including the NLRC4 and NLRP12 inflammasome have been 
linked to autoinflammatory diseases (review in13). Inflammasomopathies are defined as 
inflammasome-related diseases. These rare conditions appear to have a wide spectrum of 
phenotypes that make often the diagnosis challenging. Increased awareness of these rare 
diseases has facilitated the identification of several inflammasomes, including some that 
could contribute to inflammation in complex diseases such as arthritis. 
 
Non-NLR inflammasomes  
 
In addition to NLRs other innate immune sensors have evolved to form inflammasomes 
(Figure 1B). Among these, the Pyrin inflammasome is the best understood. Pyrin was 
initially identified as the product of the MEFV gene involved in Familial Mediterranean 
fever (FMF) 37,38. 
FMF is the most frequent monogenic autoinflammatory condition described so far. It 
differs from other inflammasomopathies in that it is inherited mostly in an autosomal 
recessive fashion, despite the fact that in FMF patients, systemic inflammation is caused 
by a gain of function in the pyrin protein causing aberrant activation of the pyrin 
inflammasome 39. It is not known why patients with only one allele mutated only rarely 
show signs of FMF. It could indicate a dose effect of MEFV mutations in FMF or that the 
presence of the natural allele dampens constitutive pyrin inflammasome formation in 
heterozygous carriers. 
Several musculoskeletal symptoms are present in FMF, including arthralgia and arthritis. 
Moreover, in individuals without apparent signs of FMF but harboring a heterozygous 
mutation in the MEFV gene, increased prevalence of seronegative rheumatoid arthritis was 
observed 40. Evidences also indicate that the MEFV gene might participate in the 
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pathogenesis of systemic onset juvenile idiopathic arthritis 41. These findings also revealed 
that gain of function in one of the MEFV alleles is sufficient to increase the risk of 
autoinflammatory arthritis, further indicating that the pyrin inflammasome may contributes 
to joint inflammation.  
The AIM2 inflammasome may also contribute to arthritis. The protein AIM2 detects free 
DNA. It assembles an inflammasome in the context of released viral and bacterial DNA as 
well as self-DNA exposed by damaged cells (review in42). In mice, using a model of 
arthritis caused by deficiency in DNAse II, AIM2 inflammasome activation was found to 
contribute to joint inflammation 43,44. Additional studies are required to investigate whether 
tissue damage or infections in the joint may trigger AIM2, thereby contributing to 
inflammation in human arthropathies. 
 
Inflammatory signals triggered by inflammasomes activation 
Inflammasome assembly originates from the activation of different platforms that respond 
to specific stimuli. Despite this complexity that probably reflect an evolutionary race aimed 
at the sensing of harmful conditions, all inflammasomes converge to the activation of one 
enzymatic function; the activation of inflammatory caspases, mainly caspase-1.  Two main 
consequences result from caspase-1 activation: cell death and cytokine release.  
IL-1β and IL-18 are the two cytokines that rely the most on caspase-1 activation. Both 
these cytokines are synthetized as precursors that require proteolytical cleavage to be fully 
active. Caspase-1 is the main protease for IL-1β and IL-18 maturation, therefore these two 
inflammatory mediators are typical products of inflammasome activation capable of 
communicating the inflammatory signal onto cells harboring IL-1β and/or IL-18 receptors 
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(Figure 2). Several inflammasomopathies can be efficiently treated with drugs that block 
these cytokines, particularly IL-1β. This is particularly evident in CAPS patients, where 
treatment with biologics that block signaling by the IL-1 receptors dampens most signs of 
systemic inflammation 45.  
Another consequence of inflammasome assembly and caspase-1 activation is the induction 
of pyroptosis. Pyroptosis is a pro-inflammatory form of cell death that is associated with 
the disruption of cellular membranes leading to the extracellular release of cytosolic 
content. IL-1β and IL-18 are synthetized in the cytosol and do not carry leader sequences 
to target them to the secretory pathway. These cytokines cannot be released by the 
“classical” pathway of secretion. In contrast the disruption of plasma membrane integrity 
observed upon inflammatory caspase activation may present the main mechanism by which 
these cytokines are released following proteolytic maturation 46. While cell death could be 
a prerequisite for the release of IL-1β and IL-18, not all cells commit to pyroptosis upon 
inflammasome assembly47,48. Therefore, alternative pathways of IL-1β and IL-18 secretion 
may exist. The identification of GSDMD as a cytosolic caspase-1 substrate, has shed some 
light on the process of pyroptosis and cytokine release 49,50. Upon cleavage GSDMD 
releases an N-terminal fragment that oligomerizes and forms pore-like structures within 
the membrane lipid bilayer. These pores have been proposed to function as conduits for 
the release of small proteins including IL-1β and IL-18 51,52. 
The formation of GSDMD pores has also been reported to disrupt membrane integrity49,50, 
a process that can trigger an adaption program aimed at repairing the damage 53. If the 
repair is unsuccessful or the damage too sizeable the GSDMD pores allow for complete 
lysis of the cell and death by pyroptosis 46.  
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While pyroptosis has been studied extensively in mice and in the context of infection with 
intracellular bacteria, its role in human inflammatory and autoimmune diseases is still 
unclear. The identification of markers and assays to monitor key features of pyroptosis in 
human tissues will help address the role of this process in humans. In particular it would 
be of interest to identify proinflammatory mediators released by damaged cells beyond IL-
1β and IL-18. It is likely that additional cytosolic components release during pyroptosis 
may contribute to aspect of inflammation and autoimmunity in damaged tissues.  
 
Cell types competent for inflammasome activation 
Inflammasome activation is a multi-step process that is tightly controlled. Most cell types 
need to be primed to become competent for inflammasome activation in vitro. This 
priming, also known as signal 1, is provided by treatment with strong proinflammatory 
stimui such as lipopolysaccharides (LPS) or phorbol myristate acetate (PMA), two 
molecules that trigger NFκB activation (Figure 2). It was postulated that these signals may 
function by promoting the induction of inflammasome components. Signal 1 may also 
promote postranslational modifications of inflammasome components required for 
activation 17. However, the exact nature of signal 1 and its function is still debated. 
Importantly, little is known about the signals that make cells competent for inflammasome 
activation in vivo in humans. The importance of signal 1 is illustrated in patients with gain 
of function mutations within inflammasome platforms such as in CAPS. While myeloid 
cells from these patients have constitutive activation of the NLRP3 protein, actual 
inflammasome assembly is only observed upon treatment of these cells with LPS 20. In 
these patients, yet unidentified signals may provide the signal 1 that contribute to IL-1β 
mediated systemic inflammation. Because there is no clear evidence that infectious events 
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may initiate inflammatory flares in CAPS, signal 1 may originate from endogenous 
processes such as low-grade inflammation involved tissue repair and homeostasis 54. 
Understanding the exact nature of signal 1 in patients with inflammasomopathies may shed 
some light on the physiological setting that contributes to inflammasome activation 
upstream of its assembly.  
It is likely that the nature of signal 1 will differ between cell types and the different 
inflammasome platforms. The context of inflammasome activation is therefore key and 
may contribute to the development of inflammasome related diseases.  Inflammasomes are 
mostly studied in cells of myeloid origin such as monocytes, macrophages, neutrophils, 
and dendritic cells. These cell types show different responses to inflammasome stimuli, for 
example, neutrophils are less susceptible to pyroptosis than macrophages47. In mice it was 
shown that differentiation protocols used to produce dendritic cells and macrophages 
determine the response to inflammasome inducers, further demonstrating how context 
affects inflammasome activation and the difficulty to extrapolate the nature and 
contribution of signal 1 from in vitro studies to physiological or pathological conditions 55.  
While poorly understood, inflammasome activation can also occur in non-phagocytic cells, 
such as T cells, endothelial cells, and epithelial cells. For example, in immune and non-
immune cells of the gut, inflammasome activation such as the NLRP6 and NLRC4 
inflammasomes contribute to the maintenance of gut microbiota and gut–brain homeostasis 
56. In T cells, the AIM2-like protein IFI16 has been shown to detect products from HIV 
infection to promote T cell pyroptosis 57.  In another study it was proposed that the 
complement cascade can engage the NLRP3 inflammasome in human T cells to direct T 
cells differentiation towards Th1 lineage 58. The T cell inflammasome has also been 
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suggested to contribute to autoimmunity. Studies in mice have shown a role for the 
inflammasome in promoting Th17 differentiation in a mouse model of autoimmune 
encephalomyelitis 59.  
Different inflammasome platforms have evolved to protect against pathogens and 
perturbations of cellular homeostasis. Inflammasomes aim for restoration of damage by 
initiating immune responses and repair mechanisms. When activation of inflammasome 
platforms is not in balance, its inflammatory effects contribute to unwarranted and 
damaging reactions such as the inflammation observed in arthritic diseases including RA 
and gout. 
 
Inflammasome in rheumatoid arthritis 
The systemic autoinflammatory disease characteristic for rheumatoid arthritis (RA) 
primarily affects joints and is driven by chronic synovial inflammation leading to 
irreversible cartilage degradation and joint destruction 60,61. With approximately 1% of the 
population affected worldwide 62, RA is among the most common inflammatory diseases 
and therefore an active topic of investigation. The involvement of inflammasomes in the 
pathogenesis of RA has been demonstrated in various studies in animal models, in genetic 
association studies as well as in samples from patients. 
In search for specific biomarkers for RA, the cytokine levels in sera and synovial fluid of 
RA patients have been investigated. Increased concentrations of many inflammatory 
cytokines were found in RA sera when compared to healthy controls, most prominently 
TNF, IL-6 and IL-1β 63. In particular the IL-1β of both serum and synovial fluid increased 
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in active disease and was associated with higher IL-18 levels in the synovial fluid 63. This 
argues for a prominent role of the inflammasome in the pathogenesis of RA (Table 1). 
Dampening of essentially all canonical inflammasomes, by gene knock-out of ASC, 
protected mice from developing arthritis in a collagen-induced arthritis model 64, and 
attenuated arthritic symptoms in an antigen-induced arthritis model 65. In contrast, gene 
knock-out of either NLRP3 or caspase-1 rendered the mice susceptible to arthritis induction 
in both models. These results are surprising given that in following years multiple studies 
using animal models of arthritis showed a significant role for NLRP3 inflammasome 6. 
These differences may reveal the involvement of multiple inflammasomes in RA whose 
function depends on the context and the presence of specific signal 1 promoting conditions. 
NLRP3 role in RA is supported by several observations. The severity of arthritis clinical 
score showed a positive correlation with NLRP3 levels in synovial tissue 66 and clinical 
features of arthritic disease could be inhibited by suppression of the NLRP3 inflammasome 
in macrophages 67. Furthermore, in an adjuvant-induced arthritis model in rats, 
upregulation of NLRP3 inflammasome components was observed in fibroblast-like cells 
isolated from the synovium 68,69. These results are in line with results obtained in mice 
lacking the A20/Tnfaip3 gene which predispose them to a RA-like disease. In this animal 
model of RA, the expression of NLRP3 inflammasome components are enhanced in 
macrophages and NLRP3 deficiency suppressed arthritis development and cartilage 
destruction 70. In addition, deficiency of caspase-1 or IL-1 receptor diminished RA-
associated inflammation and joint destruction in this study. The importance of IL-1 was 
also demonstrated in a mouse model of chronic arthritis, in which cell wall fragments of 
Streptococcus pyogenes are injected into the joint to induce inflammation 71. Mice deficient 
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for IL-1β were protected from progressing to chronic arthritis 71,72. Moreover, IL-1 
deficiency was shown to protect against antibody-induced arthritis as well 73.  
In human studies, evidence also exists that supports a role for NLRP3 inflammasome 
pathway in RA. Gene expression of NLRP3, ASC, caspase-1, IL-1β and IL-1R were 
significantly higher in PBMCs of RA patients compared to healthy controls 34,74-76 as well 
as the secretion of IL-1β 74,77. Single nucleotide polymorphisms at the NLRP3 locus are 
associated with RA susceptibility 34,75 and correlate with higher disease activity 78. A 
previously found NLRP3 polymorphism was shown not to associate with RA susceptibility 
by itself, however combined with a polymorphism within CARD8, a possible regulator of 
the inflammasome, the NLRP3 polymorphism associated with RA susceptibility and 
severity 33. In addition, CARD8 expression was lower in PBMCs of RA patients compared 
to healthy controls 34. Similar to PBMCs, cells directly isolated from the synovial fluid 
showed increased expression of inflammasome genes 79. In particular myeloid and 
endothelial cells showed enhanced expression of NLRP3, ASC and caspase-1 and were 
proposed to be the primary source of IL-1β secretion in the synovium 80. 
Inflammasome activity results in maturation of IL-1β, a cytokine heavily implicated in RA 
pathogenesis, but also IL-18. High levels of IL-18 in patients sera and synovial fluid have 
been described 63,81,82 and polymorphisms in the IL-18 gene locus were associated with 
increased risk for RA 83. Animal studies suggest that IL-18 contributes to collagen-induced 
arthritis in rats 84 as well as in a mouse models of RA elicited by treatment with the TLR2 
agonist zymosan 85. On a functional level, IL-18 was shown to promote chemotaxis of 
monocytes to the synovium 85 and angiogenesis within the arthritic joint 86. Moreover, IL-
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18 was also able to induce fibroblast-like synoviocytes to secrete pro-osteoclastic cytokines 
suggesting a role in bone resorption 87.  
Finally, a single NLRP1 gene polymorphisms was identified as a risk factor for RA 88. This 
particular polymorphism resulted in increased expression of NLRP1. In an adjuvant-
induced arthritis model in rats increased NLRP1 expression was also observed 89, and 
inhibition of NLRP1 inflammasome ameliorated the symptoms of arthritis in AIA rats as 
well as CIA mice 89-91. The prominent role of NLRP1 inflammasome in CIA mice may 
explain why NLRP3 deficiency had limited effect on arthritis induction in this animal 
mode. While the pathways and mechanisms leading to inflammasome activation is RA are 
still poorly understood, the above studies clearly show the involvement of the 
inflammasome platform and its downstream cytokines IL-1β and IL-18 in RA disease. 
Inflammasome-targeted therapies may therefore benefit RA patients and will be discussed 
below.  
 
Inflammasome in gouty arthritis 
Deposition of monosodium urate (MSU) crystals or calcium pyrophosphate dehydrate 
(CPPD) crystals in the joint underlie the development of gout or pseudogout, respectively. 
Characteristic for these autoinflammatory diseases are the flares of inflammation, causing 
fever as well as severe pain and swelling of the joint(s). Since gout has a clear cause, 
detection of crystals in the synovial fluid is adequate for diagnosis and the demand for large 
studies to identify biomarkers remained inexistent. Rather, studies focused on identifying 
risk factors for the disease and cellular mechanisms by which crystals evoke inflammatory 
reactions.  
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Several SNPs in inflammasome-relates gene loci were identified as risk factor for gout, 
including NLRP3 92, IL-1β 93 and CARD8 36 (Table 1). Moreover, genetic variants of 
PPARGC1B (peroxisome proliferator-activated receptor-y coactivator 1a) that resulted in 
increased expression of NLRP3 and IL-1β in PBMCs were significantly associated with 
gout 94. High levels of NLRP3, caspase-1, IL-1β, and IL-18 were detected in patient sera 
and/or synovial fluid 92,95-97. IL-1 signalling, as a result of inflammasome activation, is a 
very efficient signal 1 that can increase the expression of inflammasome components, 
therefore increased expression of inflammasome components may indicate the presence of 
an active inflammasome in these patients. 
Evidence from inflammasome-deficient mice supports a role for the inflammasome 
complex in gout pathology. Murine models of crystal-induced inflammation mimic the 
complex interplay that occurs between resident and infiltrating immune cells in an inflamed 
joint by injection of MSU crystals into the joint or within the peritoneal cavity 98. 
Accordingly, neutrophil infiltration towards the MSU injection site was reduced in the 
absence of functional NLRP3, ASC, or caspase-199,100. Furthermore, MSU-induced 
secretion of IL-1β was prevented in macrophages lacking NLRP3, ASC or caspase-1 100,101. 
Similar results were obtained using CPPD crystals 100.  Interestingly, inhibition of 
inflammation was observed to be more robust and sustained in IL-1R deficient animals 
compared to ASC or caspase-1 deficient animals 100, indicating that in absence of 
inflammasomes pathogenic microcrystals can activate an alternative pathway of IL-1 
activation. This could be mediated by IL-1α or may involve other proteolytic event that 
could promote IL-1β maturation such as the release of neutrophil serine proteases 72. 
 18 
MSU crystals were found to activate the complement cascade leading to active complement 
subunits C3a and C5a 102,103. Specifically, C5a induced neutrophil infiltration towards the 
site of injection and activated NLRP3 inflammasome in peritoneal macrophages through 
ROS production 103. Inhibition of C5a resulted in diminished IL-1β release 102. 
Interestingly, C5a was also found to promote NLRP3 activation in T cells 58, indicating 
that this mechanism of NLRP3 activation is relevant beyond myeloid cells and 
microcrystal-induced inflammation.  
In vitro, the addition of MSU per se did not induce inflammasome activation in murine 
BMDM or human PBMC 104,105 and was shown to require a prior priming (signal 1) of the 
cells. Various stimuli are able to prime monocytes/macrophages for inflammasome 
activation by pathogenic crystals. Indeed, priming with serum amyloid A (SAA), TLR 
ligands, or TNF warranted the capacity of MSU to activate the inflammasome and induce 
release of IL-1β in human cells 104-108. Of interest, also soluble uric acids were able to 
deliver the priming signal 109,110 however the precipitation of uric acid into MSU crystals 
was necessary for NLRP3 inflammasome activity 110. These results suggest that 
hyperuricemia, the condition of elevated systemic uric acid levels which precedes gout 
pathology, may provide the priming signal that sets of inflammasome activation once MSU 
crystals are formed and deposited. 
 
Inflammasome in spondyloarthritis 
This type of arthritis, often called ankylosing spondylitis (AS), primarily affects the spinal 
and sacroiliac joints and is characterized by vertebral fusions and bone erosions that cause 
severe and chronic pain 111,112. Of the inflammasome-related genes, those belonging to the 
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IL-1 family have been implicated in the pathogenesis of AS. Polymorphisms in the IL-1α 
or IL-1β gene locus associated with susceptibility for AS 113-117. Furthermore, a genetic 
variant of the IL-1RN allele was significantly increased in AS patients compared to healthy 
controls 115. Increased levels of IL-1β were measured in PBMCs of AS patients and active 
caspase-1 could be detected in AS synovial fluid 97,118. Although caspase-1 activity and IL-
1 release suggest a role for the inflammasome in AS, functional data is lacking to determine 
a biological relevant role for the inflammasome in this disease. A recent study comparing 
gene expressions between PBMCs of AS patients and healthy controls showed increased 
expression of NLRP3, ASC, caspase-1 and IL-1β in AS 119, yet polymorphisms in the 
NLRP3 region were not associated with the risk of AS 120. In contrast, the C10X 
polymorphisms of CARD8 was found to be associated with a decreased risk of AS 120. 
 
Inflammasome in pediatric arthritis 
The clinical spectrum of juvenile idiopathic arthritis (JIA) ranges from oligoarthritis with 
four or less joints affected, to polyarticular arthritis having more joints affected and higher 
damage, to systemic arthritis that affects many joints and also includes skin rashes and 
fever attacks (systemic-onset JIA; soJIA). Many genetic studies in JIA have been 
performed, but only a few studies link inflammasome to JIA pathogenesis. In a Taiwanese 
population a polymorphism in NLRP3 was associated with increased risk for 
oligo/polyarticular arthritis 35. A polymorphism in IL-1Ra, a negative regulator if IL-1 
signaling, was found associated with JIA patients in an Iranian population, however it was 
not specified which type of JIA was involved 121. Cytokine profile analysis of blood plasma 
revealed no differences in any of the inflammasome-activated cytokines IL-1α , IL-1β or 
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IL-18 between patients and healthy controls 122 suggesting a modest role for the 
inflammasome in oligo/articular JIA pathology.  
Systemic-onset JIA (soJIA) differs from other JIA types in pathogenesis. Its clinical 
outcome is more severe than other juvenile arthritis types and patients are at additional risk 
for developing macrophage activation syndrome (MAS) 123. Inflammasome-activated 
cytokines IL-1β and IL-18 play a significant role in soJIA. When serum of soJIA patients 
was added to healthy donor PBMCs, upregulated gene expression of IL-1β and IL1R was 
observed and secretion of IL-1β was detected 124. Direct stimulation of patient PBMCs also 
resulted in high levels of IL-1β release which was not observed in healthy donor PBMCs 
124. IL-18 serum as well as synovial fluid levels were markedly increased in soJIA and were 
shown to have a high predictive value for disease activity 122,125. Moreover, IL-18 may be 
indicative of risk to develop MAS 126. 
Because of its atypical clinical presentation, soJIA is classified as an autoinflammatory 
rather than autoimmune disorder. Symptoms of classical autoinflammatory diseases 
including CAPS and FMF overlap with soJIA including recurrent fever episodes, skin 
rashes, joint swelling and systemic inflammation 127. This suggest a possible role for 
inflammasome dysfunction in soJIA.  
Further evidence for the contribution of inflammasome biology in rheumatic diseases 
comes from the efficacy of inflammasome-targeted therapies used in rheumatic patients. 
Over the years, treatment of rheumatic diseases has evolved from complete suppression of 
inflammation with medications like glucosteroids to targeting of specific inflammatory 
pathways using specific pathway inhibitors and refined biological therapies. 
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Inflammasome-targeted therapies in arthritic diseases 
The prominent role for inflammasomes in different diseases including monogenic 
autoinflammatory diseases and more complex inflammatory disorders have provided 
strong interest in the identification and development of strategies to decrease 
inflammasome responses. Two strategies have been considered (Figure 3). The first 
approach aims at targeting the inflammasome specific cytokines IL-1β and IL-18. The 
second strategy aims at directly inhibiting specific inflammasome components.  
IL-1/IL-18 inhibitors 
Anakinra is a recombinant version of the naturally occurring endogenous IL-1ra, which is 
regularly used in the treatment of RA and autoinflammatory diseases. IL-1ra binds to the 
IL-1 receptor complex (IL-1R) without triggering a cellular signaling cascade. This binding 
results in competitive inhibition of the proinflammatory effects of IL-1. Anakinra has been 
used in RA for almost two decades (Table 1). Alternatives to Anakinra include Rilonacept 
a recombinant protein which function as a soluble decoy to prevent activation of IL-1RI 128 
and Canakinumab, a human monoclonal antibody targeting IL-1β. This antibody was 
approved for CAPS ten years ago and turned out to be very effective at inhibiting its target. 
However, in contrast to Anakinra and Rilonacept that block the biological activities of both 
IL-1β and IL-1α, Canakinumab does not block signaling by IL-1α.  
The importance of IL-1β in inflammatory diseases was supported by the results of the 
Canakinumab Anti-Inflammatory Thrombosis Outcome Study (CANTOS) 129. This large-
scale trial tested whether decreasing inflammation with Canakinumab reduced the risk of 
a second cardiovascular event in patients who previously experienced a heart attack or 
stroke. The trial demonstrated a benefit of IL-1β inhibition in atherosclerosis. Secondary 
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exploratory analysis of a the CANTOS trial also confirmed that IL-1β blockade is of 
interest in other diseases including gout130-132.   
Other biologics have been developed to block the IL-1 pathway, however are currently not 
(yet?) used in clinics. The monoclonal antibody Lutikizumab (ABT-981) has been 
engineered to target both IL-1α and IL-1β 133. Gevokizumab is an IL-1β antagonistic 
antibody that binds strongly to IL-1β without inhibiting its recruitment to the IL-R. It 
prevents the engagement of the IL-1β-IL-1R signaling complex through its allosteric 
modulation properties134.  Furthermore, reagents inhibiting the IL-1R directly have been 
developed. The AMG108 antibody binds and neutralizes IL-1R, leading to a complete 
abrogation of IL-1β and IL-1α signaling 135.  
Inhibition of IL-1β was found to be very effective in typical autoinflammatory diseases 
such as soJIA 136. Similarly, CAPS patients with gain of function NLRP3 respond 
significantly to IL-1β inhibition137 indicating that this cytokine is the most relevant product 
of NLRP3 activation in humans. 
In contrast, clinical studies suggest that the efficacy of IL-1β inhibition is modest compared 
to strategies targeting TNF in RA 138. This may indicate that beyond inflammasome 
activation, other inflammatory pathways are predominant in RA. Alternatively, this could 
support the hypothesis that other products of inflammasome activation contribute to disease 
pathology. For example, IL-18 or danger signals released during pyroptosis could play a 
proinflammatory role in RA. 
Very few reagents are available to block IL-18 in humans. In a recent clinical trial the use 
of Tadekinig alfa, a recombinant IL-18 binding protein, showed positive results in adult-
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onset Still’s disease 139, supporting the assumption that IL-18 may contribute to 
inflammation and immune deregulation in inflammasomopathies. 
 
Caspase-1 inhibitors 
The enzymatic activity of the inflammasome is executed by caspase-1 proteases. Therefore, 
these enzymes are attractive targets for pharmacological intervention. Despite two decades 
of research no drug based on caspase inhibition has been approved yet140. The main 
challenge is the design of inhibitors that only affect the inflammatory caspases without 
interfering with proapoptotic caspases. In mice, the inhibition of caspase-1 was effective 
in models of rheumatoid arthritis, osteoarthritis and psoriasis 140,141. Vx-740 and Vx-765, 
two caspase 1 inhibitors, reached phase II clinical trials for arthritis, epilepsy and psoriasis 
but were withdrawn, partially due to liver toxicity140. New insight into the mechanisms of 
action of thalidomide, an anti-inflammatory drug that was introduced more than 50 years 
ago, showed its capacity to block caspase-1 activity 142. Thalidomide is currently tested in 
various inflammatory conditions and experimentally used for the treatment of refractory 
ankylosing spondylitis. 
Colchicine  
Colchicine is a widely available, low-cost drug with a range of anti-inflammatory 
properties that has been used in the form of plant extracts as early as 1550 BC to treat joint 
swelling143. Nowadays, colchicine is commonly used for the treatment of two 
inflammasomopathies: FMF and gout 144. Moreover, colchicine anti-inflammatory effects 
have been shown to have potential benefits in other conditions such as Behcet’s disease 
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and pericarditis. Moreover, colchicine is considered in prevention or as an add-on therapy 
to current treatment in a wider spectrum of cardiovascular diseases 145. 
How colchicine inhibits inflammation is still poorly understood. Colchicine inhibits 
microtubule polymerization, a process that is involved in a variety of cellular processes 
including maintenance of cellular integrity, signal transduction, protein traffic, and cellular 
migration. Early studies showed that colchicine treatment of monocytes exposed to gout-
inducing uric acid crystals prevented the activation of the NLRP3 inflammasome 100. It was 
therefore proposed that colchicine may impair microtubule-driven events involved in the 
assembly of the NLRP3 inflammasome upon exposure to crystals or other activating 
agonist such as nigericin 146. In contrast, colchicine has little effect in CAPS patients 
harboring constitutive activation of NLRP3 suggesting that it may impact inflammasome 
activity upstream, or in the early steps, of NLRP3 activation147.  
Colchicine efficacy in FMF has indicated that this compound may also impact the Pyrin 
inflammasome. In line with this possibility, colchicine was found to block the pyrin 
inflammasome activation by bacterial toxins and infection with C. difficile. In contrast, 
monocytes from FMF patients with gain-of -function mutations in pyrin were resistant to 
inflammasome inhibition by colchicine 148. This may suggest an increased efficacy of 
colchicine in vivo compared to in vitro experiments. Alternatively, colchicine may 
modulate an additional mechanism in FMF by targeting a feedback loop or the engagement 
of other inflammasomes such as NLRP3.  
NLRP3 inhibitors  
Increasing evidence for NLRP3 inflammasome involvement in a plethora of inflammatory 
diseases has led to a sustained enthusiasm by the industry towards the development of 
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specific inhibitors.  Development of such drugs is facilitated by studies in CAPS patients 
providing a first and robust testing ground to evaluate the efficacy and specificity of new 
molecules in blocking NLRP3-mediated inflammation in this NLRP3-driven disease. 
NLRP3 inhibition is considered for evaluation in rheumatoid arthritis, atherosclerosis, 
neurodegenerative disorders and obesity-related diseases 149. Several molecules have been 
shown to target NLRP3 150, and a number of these compounds have promising NLRP3 
inhibitory activities. 
The compound MCC950 (also known as CRID3) is the NLRP3 inhibitor that has been the 
most studied to date151,152. MCC950 inhibits NLRP3 by directly interacting with the 
NLRP3 ATPase domain, thereby blocking ATP hydrolysis and NLRP3 oligomerization 
151,153. Several studies have shown therapeutic efficacy of MCC950 in a variety of 
preclinical mouse models, including atherosclerosis, experimental autoimmune 
encephalomyelitis, diabetes, steatohepatitis and colitis 17. First, before its identification as 
a NLRP3 targeting molecule, MCC950 was discovered as an inhibitor of IL-1β activation. 
This led to the initiation of a clinical trial testing its efficacy in rheumatoid arthritis. 
Unfortunately, the trial was suspended due to drug toxicity 17.  
Similar to MCC950, a compound called Tranilast was found to bind to the NACHT domain 
of NLRP3, abolishing its ability to assemble into an inflammasome154. This molecule is an 
analogue of a tryptophan metabolite, that was initially identified as an anti-allergy drug 
and is presently used in several inflammatory and autoimmune conditions155. RA studies 
in mice have shown that treatment with Tranilast reduced disease in models of collagen-
induced arthritis156,157 and in arthritis induced by adjuvant and streptococcal cell wall 
products in rats 158. Its mode of action is still unclear and may not involve inhibition of 
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NLRP3 ATPase activity 154. Tranilast has very low adverse effects, therefore if further 
studies demonstrate its efficacy and specificity at inhibiting NLRP3, its repositioning in 
inflammasomopathies could be of great interest and may provide a new therapeutic tool 
for treating complex diseases with NLRP3 involvement.  
The compound CY-09, an analogue of the inhibitor for cystic fibrosis transmembrane 
conductance regulator channel (CFTR), was recently identified to efficiently inhibit 
NLRP3159. CY-09 specifically binds to the ATPase domain of NLRP3 thereby blocking 
NLRP3 oligomerization. Preclinical studies showed that CY-09 was efficient at decreasing 
inflammation in a mouse model of CAPS. Ex-vivo it was found to decrease IL-1β secretion 
in synovial fluid cells (SFCs) from a patient with gout 159. Therefore, this molecule could 
be a candidate for further studies in human arthritic disease.   
The Isodon plant, Rabdosia rubescens, and its extracts, were shown in East Asian herbal 
medicine to have anti-inflammatory properties.  Oridonin, a bitter tetracycline diterpenoid 
compound, was identified as the active compound of these plants extracts 160. While the 
mechanism of Oridonin is still unclear, it was shown to inhibit the NLRP3 inflammasome 
161. Oridonin decreased the ability of NLRP3 to interact with NEK7, a protein that may 
modulate its activation 161. 
OLT1177 is a small non-lipophilic molecule that was found to inhibit the NLRP3 
inflammasome 162and demonstrated suppressed joint inflammation in murine models of 
acute arthritis163. How OLT1177 blocks NLRP3 engagement is still unclear, however the 
preclinical studies in mice indicate that this molecule could be a promising compound to 
test in patients with joint disorders.  
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Several studies have suggested that certain compounds may function as inflammasome 
inhibitors including Gyburide164, INF39165, BOT-4-one 166, MNS167, Bay 11-7082168 and 
parthenolide 168. The specificity and efficacy in humans of these compounds need to be 
further evaluated. However, it is clear that the collection of putative NLRP3 inhibitors is 
growing fast. The challenge will be to identify the safest and specific compound that will 
provide the most potent therapeutic benefit to patients.  
 
CONCLUSIONS AND PERSPECTIVES 
The importance of the inflammasome in autoinflammatory diseases has become evident 
over the past twenty years. In particular genetic studies revealed a contribution of gene 
variants of inflammasome components to susceptibility for inflammatory diseases 
including RA, gout and AS (Table 1). While the functionality of some gene 
polymorphisms were uncovered, further studies are needed to elucidate the role of 
identified SNPs on inflammasome activity in the context of arthritis. Patients with arthritic 
diseases have greatly benefited from the development of inflammasome-targeting 
biologicals and will continue to do so in upcoming years. Research into the mechanisms of 
different inflammasome activation has spiked, which will fuel the possibility for designing 
highly specific and efficient inhibitors. With the recent discovery of GSDMD as a major 
driver of pyroptosis, small molecule inhibitors that block GSDMD function are expected 
to emerge for possible treatment of inflammatory conditions including arthritis. Moreover, 
clinical efficacy of the diverse selection of NLRP3 inhibitors under development will come 
from trials which are typically performed in CAPS patients. While CAPS is a rare disease, 
these inhibitors could become blockbuster drugs provided that their efficacy will be 
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confirmed in more common inflammatory diseases. To facilitate efficient transition of 
newly discovered inhibitors to (pre)-clinical studies, using human cellular models over 
animal models is imperative. Differences between human and mouse inflammasome 
biology, such as the lack of CARD8 in mice, impacts conclusions about treatment 
efficacies obtained with murine disease models. Through design of relevant cellular models 
incorporating patient mutations or direct use of patient-derived cells we may identify 
clinically beneficial treatments faster and with more certainty.         
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Figure legends:  
Figure 1. Schematic overview of inflammasome platforms. The structure and domain 
interactions of Nod-like receptor (NLR) inflammasomes (A) and non-NLR 
inflammasomes (B) are depicted. NLRP3, Pyrin and AIM2 all contain a N-terminal 
recruitment domain PYD whereas NLRC4 contains a CARD domain at its N-terminus. 
PYD-PYD interactions occur with the adaptor protein ASC which in turn interacts with 
Caspase-1 through CARD-CARD interactions. The N-terminal CARD domain of NLRC4 
directly interacts with Caspase-1. NLRP1 harbors its CARD recruitment domain at the C-
terminus which also directly interacts with Caspase-1.  
 
Figure 2. Local and systemic effects of inflammasome activation. Innate immune cells 
such as monocytes and neutrophils receive priming signals (signal 1) that induce NFκB 
activation. NFκB upregulates gene transcription of inflammasome components NLRP3, 
Caspase-1 and ASC, as well as inflammasome substrates proIL1-β, proIL-18 and GSDMD. 
Upon delivery of inflammasome activation signals (signal 2) assembly of the 
inflammasome complex occurs which results in activation of the caspase1 enzyme now 
able to cleave its substrates. Cleaved GSDMD forms membrane pores through which 
mature cytokines IL-1β and IL-18 are secreted. IL-1β and IL-18 bind to their receptors IL-
1R and IL-18R, respectively. IL-1R/IL-18R signalling drives various local and systemic 
reactions including a positive inflammasome feedback loop by providing signal 1, 
stimulation of many different target cells that promote activating a local inflammatory 
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response, and initiation of systemic inflammatory functions such as neutrophil recruitment, 
fever and production of acute phase proteins. 
 
Figure 3. Inhibitors targeting inflammasome activity. The molecular targets of selected 
anti-inflammatory drugs are depicted. Inhibitors for which inhibition of inflammasome was 
observed, however the molecular target is unknown are listed directly beneath the 
inflammasome complex. Arthritic diseases are commonly treated with Anakinra, 
Rilonacept, Canakinumab, Thalidomide or Colchicine depending on the disease type. 
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